Evidence map›Paper›PMID 39609922›Full record

ArticleJournal of medical case reports2024

Late relapse of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: a case report.

Hamidreza Amiri, Mehdi Karimi, Fakhreddin Shariatmadari

Abstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hamidreza AmiriStudent Research Committee, Arak University of Medical Sciences, Arak, Iran.
Mehdi KarimiFaculty of Medicine, Bogomolets National Medical University, Kyiv, Ukraine. dr.mehdii.karimi@gmail.com.ORCID http://orcid.org/0009-0006-4388-0214
Fakhreddin ShariatmadariDepartment of Pediatrics, Arak University of Medical Sciences, Arak, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-N-methyl-D-aspartate receptor encephalitis is a sporadic autoimmune disorder of the brain that presents in a variety of neuropsychiatric manifestations, including seizures, psychosis, and alterations in behavior. N-methyl-D-aspartate receptor is primarily seen in young females. Although this disease can be treated, it can relapse in rare cases. Relapsing typically occurs within the early years following the initial episode and is exceedingly rare after 5 years. CASE PRESENTATION: In this case study, we report on a 16-year-old Iranian female experiencing a relapse of anti-N-methyl-D-aspartate receptor encephalitis 8 years after her initial diagnosis. She was admitted to the hospital with dysphasia (a speech disorder) and dyslexia (reading and writing impairment). A thorough clinical evaluation revealed the presence of anti-glutamate receptor type N-methyl-D-aspartate receptor antibodies in her serum and cerebrospinal fluid, confirming the diagnosis. Following treatment with immunotherapy and plasmapheresis, she made a complete recovery.

conclusionThis case of relapsing anti-N-methyl-D-aspartate receptor encephalitis, occurring more than 5 years after the initial episode, is exceptionally rare. This late relapse underscores the importance of long-term follow-up for patients with this condition.

Indexed as

Anti-N-Methyl-D-Aspartate Receptor EncephalitisPlasmapheresisRecurrenceAdolescentAutoantibodiesDyslexiaFemaleHumansImmunotherapyReceptors, N-Methyl-D-AspartateTreatment OutcomeAutoantibodiesReceptors, N-Methyl-D-AspartateAnti-NMDA antibodyAnti-NMDA encephalitisAnti-N-methyl-d-aspartate receptor encephalitisAutoimmune encephalitisCase reportRelapsing encephalitis

Identifiers

PMID39609922
PMCPMC11605960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.